Hummingbird Bioscience Licenses Monoclonal Antibodies To Immunome For Exclusive Worldwide Use, Receives Upfront Payment And Potential Milestone Payments, Royalties
Hummingbird Bioscience Licenses Monoclonal Antibodies To Immunome For Exclusive Worldwide Use, Receives Upfront Payment And Potential Milestone Payments, Royalties
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.
Hummingbird Bioscience是一家为难以治疗的疾病发现和开发变革性生物制剂的精准生物治疗公司，该公司今天宣布，它已授予Immunome, Inc.（纳斯达克股票代码：IMNM）一家专注于开发同类首创和同类最佳靶向癌症疗法的生物技术公司全球独家许可，发放针对单一未公开靶标的单克隆抗体。
Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for future development and commercial milestone payments, as well as royalties.
根据许可协议的条款，Immunome将负责含有这些抗体的产品的研究、开发、制造和商业化。Hummingbird Bioscience将获得预付款，并将有资格获得未来的开发和商业里程碑付款以及特许权使用费。
